Glutathione for detox then steps in during Phase II, where it conjugates with these modified toxins, attaching itself to them and transforming them into water-soluble compounds [5]
Newer data suggest a significant reduction in cardiovascular events with GLP-1 agonist therapy in patients who are overweight or obese and have a prior history of heart disease
Special Population Considerations Certain populations may need modified protocols
"For the newer GLP-1 medications, it would be useful to look at whether there are genetic variants, like the variants in PAM , that explain poor responders to their medications." "There are a whole class of medications that are insulin sensitizers, so perhaps we can develop medications that will allow people to be sensitized to GLP-1s or find formulations of GLP-1, like the longer-acting versions, that avoid the GLP-1 resistance." The research has been published in Genome Medicine .
Biothiols and oxidative stress markers and polymorphisms of TOMM40 and APOC1 genes in Alzheimer's disease patients